Clinical Trials Logo

Cerebrovascular Disorders clinical trials

View clinical trials related to Cerebrovascular Disorders.

Filter by:

NCT ID: NCT03689387 Completed - Clinical trials for Cerebral Vascular Disorder

Evaluation of Physical Activity Practice (AP) After Cerebral Vascular Stroke (Stroke)

QAP-AVC
Start date: October 23, 2017
Phase:
Study type: Observational

Physical activity is defined by any movement produced by the skeletal muscles responsible for an increase in energy expenditure. The Stroke Council of the American Heart Association (AHA) recommends, in prevention after the occurrence of a first stroke, the practice of moderate to intense physical activity for 40 minutes a day, three to four times a week (Lackland et al., 2014). The World Health Organization (WHO) also recommends the practice of at least 150 minutes of moderate-intensity endurance activity or at least 75 minutes of endurance activity of sustained intensity per week, adapted to the possibilities of the patient (World Health Organization 2010). Unfortunately, the majority of stroke patients have activity below recommendation (Rand et al., 2009). The main hypothesis of this work is that the amount of AP, measured by self-questionnaire, is insufficient, and below current recommendations in patients with stroke, after return home. Given the multiple physical, psychological, social, and economic benefits of PA practice, it is also important to identify the habits and challenges that patients experience with PA, so that they can be better informed. advise and guide them to reach AP stroke recommendations.

NCT ID: NCT03679858 Recruiting - Clinical trials for Cerebrovascular Disorders

Platelet Antisedimentation Rate and Multiplate Exams in Patients on Antiplatelet Therapy and Controls

Start date: January 1, 2018
Phase:
Study type: Observational

To search for simple laboratory methods selecting patients with low/non-responsiveness to P2Y12 receptor antagonists.

NCT ID: NCT03675958 Not yet recruiting - Clinical trials for Spasticity as Sequela of Stroke

Immediate Effect of Johnstone's Pressure Splint Added to Stretching on the Spasticity in Cerebrovascular Disease.

Start date: September 24, 2018
Phase: N/A
Study type: Interventional

TITLE: Immediate effect of Johnstone's Pressure Splint added to Stretching on the spasticity of elbow flexors and wrist in Cerebrovascular Disease (CVD). INTRODUCTION: In the rehabilitation of the upper limb post-CVD to employed exercise modalities such as stretching (S) to control spasticity, improve mobility and functionality. Also it is used the Johnstone´s Pressure Splint (JPS), which exerts circumferential pressure and contribute to spastic pattern inhibition, sensory re-education and increased of the mobility. OBJECTIVE: The aim of the study is to evaluate the immediate effect of JPS added to S on the spasticity of elbow flexors and wrist, the reflex excitability and the joint kinematics in Stroke. MATERIALS AND METHODS: A randomized experimental study with two intervention groups will be performed. Control group (GS): Stretching and experimental group: (GJPS + S): JPS plus S. Measurement times: Before the intervention (T0) and immediately post- intervention (T1). The outcome variables are muscle tone of elbow, wrist and hand assessed with the Modified Ashworth Scale (MAS); H reflex of the Flexor Carpi Radialis muscle, latency (ms), duration (ms) and amplitude (mV) of the M and H waves, and the amplitude the Hmax / Mmax ratio (%). Shoulder, elbow and trunk angles (degrees), trunk displacement (cm) and duration (sec) of the Functional Reach Pattern (PAF) will be evaluated with the software Contemplas. ANALYSIS: Descriptive statistics will be applied and Shapiro Wilk test to evaluate the normality of the variables. Intra-group differences will be assessed with the student t-test paired and intergroup with the student t-test unpaired or the sum of Wilcoxon rank according to the distribution of the variables. EXPECTED RESULTS: Hypotheses and contributions to the scientific evidence on the immediate effect of the S and JPS will be generated, to support the JPS as a complement to the traditional treatment. The results will be socialized in an international scientific event and a publication will be submitted to an impact journal. KEY WORDS: Spasticity, H Reflex, Johnstone's Pressure Splint, Stretching, Functional Reach.

NCT ID: NCT03589053 Recruiting - Clinical trials for Ischemic Cerebrovascular Disease

Limb Remote Ischemic Conditioning and Cerebrovascular Reserve

Start date: October 8, 2018
Phase: Phase 2
Study type: Interventional

Cerebrovascular reserve (CVR), defined as the increase in cerebral blood flow (CBF)in response to a vasodilatory stimulus, is known to reflect the compensative capacity of the brain to maintain adequate blood flow in the face of decreased perfusion due to arterial stenosis. CVR dysfunction has been identified as an independent risk factor for ischemic stroke. Limb remote ischemic preconditioning (LRIC) has been suggested as a protective therapeutic modality against brain ischemia. So it is worth to detect whether LRIC can improve the CVR ability in ischemic cerebrovascular disease patients.

NCT ID: NCT03586258 Recruiting - Clinical trials for Cerebrovascular Disorders

Neuropsychological and Brain Medical Imaging Study in Patients With Brain Damage 2

CORAC2
Start date: July 2018
Phase: N/A
Study type: Interventional

Two groups of subjects will be constitute: (i) patients with circumscribed brain injury (including stroke, vascular malformations, tumor or circumscribed infectious lesions) or degenerative/developmental disorders and selective cognitive disorders; (ii) healthy control subjects. The objective of this project is to evaluate specific neuropsychological deficits and apply current brain imaging techniques (anatomical, diffusion, functional, magnetic stimulation) to patients suffering from these cognitive deficits due to brain damage, in order to elucidate the brain mechanisms underlying these deficits.

NCT ID: NCT03544801 Recruiting - Clinical trials for Cerebrovascular Disorders

Renji Cerebral Small Vessel Disease Corhort Study

RCCS
Start date: September 29, 2015
Phase:
Study type: Observational

We aim to make clear the impact with the mechanisms of variant pathological injuries on the outcomes of CSVD, to find independent imaging markers and establish prediction model of it.

NCT ID: NCT03491111 Recruiting - Clinical trials for Cerebrovascular Disorders

The Outcome of Respiratory Muscle Training in Stroke Patients

Start date: May 1, 2016
Phase: N/A
Study type: Interventional

Stroke survivors commonly have respiratory muscle weakness, swallowing disturbance, general weakness, reduced the daily living activities and short of motivation for rehabilitation. Respiratory muscle training (RMT) has been reported to improve the pulmonary function, respiratory muscle strength, exercise capacity, sensation of dyspnea and quality of life in several diseases, but rare in stroke patients. Reviewing previous reports, the protocol, intensity and duration of respiratory muscle training is still variable. Purpose: To investigate the feasibility and efficacy of respiratory muscle training on cardio-pulmonary function, swallowing function, cough function and reduction of incidence of pneumonia in post-stroke patients. Methods: A prospective, single blinded, randomized study. Consecutive patients with diagnosis of stroke will be proved by magnetic resonance image or computerized tomography. Stroke patients, aged 35-80 years old, with inspiratory muscle weakness or swallowing disturbance will be enrolled and randomly divided into control group (usual rehabilitation alone) and experimental group [inspiratory muscle training (IMT) group for patients with inspiratory muscle weakness and expiratory muscle strengthening training (EMT) for patients with swallowing disturbance]. Each patients will receive usual rehabilitation. The investigator expect that RMT will be practical for the restoration of respiratory muscle, swallowing function, cough function and voice quality, thereby reduction of the incidence of pneumonia.

NCT ID: NCT03481777 Recruiting - Ischemic Stroke Clinical Trials

Remote Ischemic Conditioning in Patients With Acute Stroke (RESIST)

RESIST
Start date: April 3, 2018
Phase: N/A
Study type: Interventional

Our primary aim is to investigate whether remote ischemic conditioning (RIC) as an adjunctive treatment reduce neurological impairment at 24 hours and improve long-term recovery in acute stroke patients as an adjunct to standard treatment.

NCT ID: NCT03471169 Recruiting - Clinical trials for Cerebrovascular Disease

Individualized Antithrombotic Therapy for Patients With Ischemic Cerebrovascular Disease

Start date: April 1, 2017
Phase: Phase 1
Study type: Interventional

To investigate the therapeutic effect of individualized treatment of antiplatelet in secondary prevention of ischemic stroke.

NCT ID: NCT03462121 Recruiting - Clinical trials for With or Without Coexisting Cerebrovascular Disease

A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease

Start date: March 1, 2018
Phase: Phase 2
Study type: Interventional

This study is a randomized, double-blind, placebo-controlled, multicentre, Phase 2 study, with an optional open-label extension, to evaluate the safety, tolerability, and efficacy of RPh201 in subjects with mild to moderate AD who are eligible for enrollment in this study. Subject participation will include a Screening Phase, Treatment Phase, and an Optional Open-Label Extension. The Screening Phase will be up to 4 weeks prior to randomization. Both the subject and their study partner(s) will sign an informed consent form (ICF). At Visit 2, Subjects will be randomized 2:1 to RPh201 or placebo. The Treatment Phase will last for 6 months post-randomization, or until subject withdrawal from the study, whichever comes first. The Optional Open-Label Extension will begin once a subject has completed the Treatment Phase and the subject and their study partner(s) have signed an ICF to continue on the study. The Optional Open-Label Extension will continue for 6 months, or until subject withdrawal from the study, whichever comes first. Subjects who do not participate in the Optional Open-Label Extension will be asked to return for an optional post-study visit 6 months after the end of the Treatment Phase. Subjects may participate in an optional biomarker sub-study. Up to 15 subjects may also participate in an optional FDG-PET sub-study during their study participation. Separate informed consent will be required for both of these sub-studies.